Skip to main content

Table 2 Inspiratory capacity on Day 1 and at Weeks 12 and 26 in the FAS population

From: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

 

Inspiratory capacity, L

p-value

 

NVA237 50 μg

(n = 534)

Placebo

(n = 260)

Difference

 

Day 1

    

   25 min

2.110 ± 0.0148

1.930 ± 0.0194

0.181 ± 0.0212

< 0.001

   1 h 55 min

2.166 ± 0.0157

1.978 ± 0.0210

0.189 ± 0.0230

< 0.001

   3 h 55 min

2.139 ± 0.0164

1.970 ± 0.0217

0.169 ± 0.0232

< 0.001

   23 h 40 min

2.019 ± 0.0168

1.915 ± 0.0222

0.104 ± 0.0239

< 0.001

Week 12

    

   -20 min

1.967 ± 0.0221

1.883 ± 0.0281

0.084 ± 0.0286

0.003

   25 min

2.048 ± 0.0216

1.900 ± 0.0274

0.148 ± 0.0278

< 0.001

   1 h 55 min

2.103 ± 0.0232

1.923 ± 0.0297

0.180 ± 0.0305

< 0.001

   3 h 55 min

2.040 ± 0.0218

1.898 ± 0.0285

0.142 ± 0.0300

< 0.001

   23 h 40 min

2.009 ± 0.0212

1.912 ± 0.0282

0.097 ± 0.0296

< 0.001

Week 26

    

   -20 min

1.988 ± 0.0202

1.879 ± 0.0267

0.109 ± 0.0281

< 0.001

   25 min

2.055 ± 0.0205

1.905 ± 0.0272

0.150 ± 0.0285

< 0.001

   1 h 55 min

2.107 ± 0.0214

1.929 ± 0.0288

0.178 ± 0.0309

< 0.001

   3 h 55 min

2.080 ± 0.0206

1.915 ± 0.0283

0.165 ± 0.0304

< 0.001

   23 h 40 min

1.997 ± 0.0192

1.884 ± 0.0257

0.113 ± 0.0275

< 0.001

  1. Values are least squares means ± standard errors